Atopic Dermatitis
Conditions
Brief summary
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: * Change in disease activity after 16 and 24 weeks * Change in subject and family quality of life after 16 and 24 weeks * Change in sleep quality after 16 and 24 weeks * Change in anxiety after 16 and 24 weeks * Change in depression after 16 and 24 weeks * Safety and tolerability
Detailed description
28 weeks
Interventions
None listed
Sponsors
Sanofi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL * Signed informed consent * 18 years and older (study questionnaires are validated for this age group). Patient is able to follow the prescribed regimen, routine follow-up visits and to fill the questionnaires
Exclusion criteria
\- Patient not eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The regression coefficient for at least 75% reduction in the Eczema Area and Severity Index score (EASI75) at week 24 adjusted to baseline characteristics predicting the change in EQ-5D utility | At Week 24 |
Secondary
| Measure | Time frame |
|---|---|
| Change in subject generic quality of life (European Quality of Life Five Dimension questionnaire (EQ-5D) utility) | At Week 16 and Week 24 |
| Change in Dermatology Life Quality Index (DLQI score) | At Week 16 and Week 24 |
| Change in Family Dermatology Life Quality Index (FDLQI score) | At Week 16 |
| Change in sleep quality (Jenkins Sleep Evaluation Questionnaire (JSEQ) score) | At Week 16 and Week 24 |
| Change in anxiety (Clinically Useful Anxiety Outcome Scale (CUXOS) score) | At Week 16 and Week 24 |
| Change in disease activity (Eczema Area and Severity Index (EASI) score) | At Week 16 and Week 24 |
| Total number of adverse events | At Week 16 and Week 24 |
| Number of serious adverse events (SAEs) | At Week 16 and Week 24 |
| Number of non-serious adverse events (non-SAEs) | At Week 16 and Week 24 |
| Total number of discontinuations | At Week 16 and Week 24 |
| Reasons for discontinuations | At Week 16 and Week 24 |
| Change in depression (Clinically Useful Depression Outcome Scale (CUDOS) score) | At Week 16 and Week 24 |
Countries
Czechia
Outcome results
None listed